Lonza Group AG stock (CH0013841017): shares under pressure after guidance cut and CEO change

Lonza Group AG has cut its 2026 margin targets and announced a change at the top, sending the Swiss health?care supplier’s shares sharply lower. What is behind the profit warning, and how does the updated strategy reshape the outlook for US?focused investors?

Lonza Group AG has moved back into the spotlight after the Swiss contract manufacturer for the pharmaceutical and biotech industry lowered its medium-term profitability targets and announced a CEO transition, developments that triggered a marked share price setback on the SIX Swiss Exchange, according to Lonza strategic update as of 10/23/2025 and subsequent market coverage from Reuters as of 10/23/2025.

In the strategic update, Lonza cut its 2026 core EBITDA margin ambition to the low 30s percentage range from previously mid?30s and warned of slower ramp?up contributions from some new biologics facilities, while also confirming the planned departure of its then?CEO and naming an internal successor, according to Lonza strategic update as of 10/23/2025.

As of: 10.06.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Lonza
• Sector/industry: Life sciences, pharma and biotech outsourcing (CDMO)
• Headquarters/country: Basel, Switzerland
• Core markets: Global biopharma customers with strong exposure to North America and Europe
• Key revenue drivers: Biologics manufacturing, small molecules, capsules and consumer health ingredients
• Home exchange/listing venue: SIX Swiss Exchange (ticker LONN)
• Trading currency: Swiss franc (CHF)

Lonza Group AG: core business model

Lonza positions itself as a leading contract development and manufacturing organization (CDMO) serving pharmaceutical, biotech and nutrition companies across the value chain from early?stage development to commercial?scale production, according to company materials in its 2024 annual report published on 01/31/2025 and the corporate profile on its website as of 03/15/2025.Lonza annual report 2024 as of 01/31/2025Lonza company overview as of 03/15/2025

The group operates four main segments: Biologics, Small Molecules, Capsules & Health Ingredients and Other Services, with Biologics representing the largest contributor to sales and profitability in recent years, according to the 2024 annual report published on 01/31/2025.Lonza annual report 2024 as of 01/31/2025

In its Biologics business, Lonza offers mammalian and microbial manufacturing, antibody?drug conjugates and cell?and?gene?therapy services, targeting biopharma innovators that prefer to outsource rather than build their own production assets, according to product descriptions on the company’s website as of 03/15/2025.Lonza pharma & biotech overview as of 03/15/2025

The Small Molecules segment focuses on active pharmaceutical ingredient development and manufacturing, while Capsules & Health Ingredients supplies gelatin and vegetarian capsules, as well as nutritional ingredients for consumer health brands, as outlined in the 2024 annual report published on 01/31/2025.Lonza annual report 2024 as of 01/31/2025

Lonza’s strategy emphasizes long?term contracts with large pharmaceutical and biotech customers, often under multi?year capacity reservation agreements that can span a decade or more, creating a comparatively visible revenue pipeline, according to management commentary in its 2024 earnings presentation dated 01/31/2025.Lonza FY 2024 results presentation as of 01/31/2025

The company highlights a capital?intensive model, in which it builds and expands biologics facilities in locations such as Visp in Switzerland and Portsmouth and Houston in the US, aiming to capture structural growth in biologics and advanced therapies, according to the same 2024 results documents and project descriptions dated 01/31/2025.Lonza FY 2024 results presentation as of 01/31/2025

Main revenue and product drivers for Lonza Group AG

According to the 2024 annual report published on 01/31/2025, Lonza generated a significant share of its sales from the Biologics division, which includes commercial manufacturing for monoclonal antibodies and other complex biologics used in oncology, immunology and other specialty indications.Lonza annual report 2024 as of 01/31/2025

Another important growth area has been cell and gene therapy manufacturing, where Lonza supplies process development and clinical?stage manufacturing services for gene?modified cell therapies and viral vectors, as highlighted in business updates on its website as of 03/15/2025.Lonza cell and gene expansion update as of 06/18/2024

Within Capsules & Health Ingredients, Lonza counts both pharmaceutical companies and consumer health and nutrition brands as customers for its capsule technologies and ingredient solutions, offering a diversified revenue base that is less tied to single blockbuster drugs, as described in segment commentary in its 2024 annual report of 01/31/2025.Lonza annual report 2024 as of 01/31/2025

Geographically, Lonza reports substantial exposure to North America, Europe and, to a lesser extent, Asia?Pacific, reflecting the global spread of its customer base but with a concentration in US and European biopharma markets, according to regional sales data disclosed in the 2024 annual report published on 01/31/2025.Lonza annual report 2024 as of 01/31/2025

Capex intensity is a key driver of future revenues, as the company continues to invest in new biologics capacity, with several large?scale projects scheduled to come online over the coming years, although management has recently cautioned that some ramps will be slower than initially planned, according to the strategic update of 10/23/2025.Lonza strategic update as of 10/23/2025

In terms of contract structures, Lonza often signs long?term agreements with innovators, which can include upfront payments and take?or?pay components, but also exposes the company to project?specific risks if customers change clinical plans or commercial expectations, according to commentary in its 2024 full?year earnings call transcript dated 01/31/2025.Lonza FY 2024 results transcript as of 01/31/2025

The company has pointed to a robust pipeline of late?stage projects and commercial products in its biologics network, while also stressing the need to optimize its portfolio and adjust capacity deployment in light of evolving demand patterns, as outlined in its capital markets day presentation dated 05/07/2025.Lonza capital markets day 2025 as of 05/07/2025

Recent earnings and guidance changes

For full?year 2024, Lonza reported sales and core EBITDA that were broadly in line with its updated guidance, but it also flagged ongoing margin pressures from the ramp?up of new facilities and a changing product mix, according to its full?year 2024 results release published on 01/31/2025.Lonza full?year 2024 results as of 01/31/2025

In the same release, the company outlined expectations for 2025, indicating mid?single?digit to high?single?digit sales growth at constant currency and a core EBITDA margin in the low?to?mid 30s percentage range, with the caveat that exact numbers would depend on the timing of project milestones and facility utilization, according to the document dated 01/31/2025.Lonza full?year 2024 results as of 01/31/2025

The subsequent strategic update on 10/23/2025, however, reduced the 2026 core EBITDA margin ambition from the mid?30s to the low?30s percentage range, citing slower contributions from certain large?scale biologics operations and a more cautious view on near?term demand for some technologies, according to the company’s statement and Reuters coverage on the same day.Lonza strategic update as of 10/23/2025Reuters as of 10/23/2025

Management also noted that, despite the near?term margin reset, the company continues to see attractive long?term growth in biologics and advanced therapies, supporting further investments, albeit with a more disciplined approach to returns and capacity planning, according to the same strategic update dated 10/23/2025.Lonza strategic update as of 10/23/2025

The combination of moderated margin ambitions and continued high capital spending has prompted some investors to reassess the company’s medium?term free?cash?flow profile, as reflected in commentary from several sell?side notes summarized in financial press coverage around the time of the update, including an article from 10/24/2025 discussing market reaction to the news.Financial press coverage as of 10/24/2025

CEO transition and strategic implications

On 10/23/2025, Lonza announced that its then?CEO would step down and that an internal candidate had been appointed as the new chief executive, with the transition designed to support the next phase of the company’s strategy, according to the strategic update and leadership announcement released on the same day.Lonza CEO transition announcement as of 10/23/2025

The board emphasized continuity in the company’s long?term growth pillars, such as biologics and cell and gene therapy, but also highlighted a stronger focus on capital discipline and return on invested capital, signaling potential adjustments to project prioritization and portfolio management, according to statements included in the leadership update dated 10/23/2025.Lonza CEO transition announcement as of 10/23/2025

Some investors and analysts have interpreted the leadership change, in combination with the guidance cut, as a reset of expectations that may pave the way for a more measured expansion strategy, potentially reducing execution risks in large?scale facility ramps, as discussed in summaries of analyst reactions in business media on 10/24/2025.Reuters as of 10/24/2025

At the same time, the new CEO inherits ongoing complex projects in the US and Europe, where on?time delivery and commercial uptake will be critical to achieving the revised margin targets and regaining investor confidence, according to the same coverage and company commentary as of 10/24/2025.Reuters as of 10/24/2025

Why Lonza Group AG matters for US investors

Although Lonza is headquartered in Switzerland and listed on the SIX Swiss Exchange, the company serves many US?based pharmaceutical and biotech firms and operates manufacturing sites in the United States, linking its fortunes closely to the US drug development and commercialization cycle, according to its site network overview and regional sales disclosure in the 2024 annual report of 01/31/2025.Lonza locations overview as of 03/15/2025Lonza annual report 2024 as of 01/31/2025

For US investors who follow the health?care and biotech sectors, Lonza offers exposure not to a single therapy but to a broad array of customer programs, functioning as a picks?and?shovels provider to the biopharma industry, with revenue tied to volumes and contracts rather than individual drug pricing in the US market, according to descriptions in its investor presentations dated 05/07/2025.Lonza capital markets day 2025 as of 05/07/2025

US?based funds can access Lonza primarily via its Swiss listing, and the stock is often referenced in thematic discussions on CDMOs and health?care outsourcing, where factors such as FDA approval timelines, US biopharma funding conditions and pipeline momentum can indirectly affect Lonza’s capacity utilization and contract flow, as reflected in sector commentary from major brokers summarized in US financial media as of 02/20/2025.Bloomberg as of 02/20/2025

Conclusion

Lonza Group AG is navigating a complex phase of heavy investment and adjusted profitability ambitions, highlighted by its 2025 guidance cut and upcoming CEO transition, even as it continues to underline long?term demand for biologics and advanced therapies, according to company disclosures and market coverage from late 2025.Lonza strategic update as of 10/23/2025Reuters as of 10/23/2025

For US?focused readers following the health?care supply chain, the stock offers exposure to outsourced manufacturing trends that are deeply linked to the US biotech and pharmaceutical ecosystem, but it also reflects the execution challenges and capital?intensity inherent in scaling complex biologics infrastructure, as described in its 2024 and 2025 investor materials.Lonza annual report 2024 as of 01/31/2025

Ultimately, the share price reaction to guidance changes, coupled with the evolving strategic priorities of the new leadership team, underscores how closely investors are tracking Lonza’s ability to balance growth, margins and capital returns within a globally competitive CDMO landscape.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.